The Role of Corticosteroids in Today\u27s Oral and Maxillofacial Surgery by Zandi, Mohammad
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 21 
 
 
 
 
© 2012 Zandi, licensee InTech. This is an open access chapter distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
The Role of Corticosteroids in Today's  
Oral and Maxillofacial Surgery 
Mohammad Zandi 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/48655 
1. Introduction 
Corticosteroids are group of hormones with similar chemical formulas which are secreted 
by adrenal cortex. The very slight differences in molecular structure of various 
corticosteroids give them very different functions. The hormonal steroids are classified 
according to their biologic effects as glucocorticoids, which mainly affect intermediary 
metabolism and the immune system, and mineralocorticoids , which have principally a salt-
retaining activity. Of large number of steroids released into the circulation by adrenal cortex, 
two are of greater importance – aldosterone, which is a mineralocorticoid, and cortisol, 
which is a glucocorticoid. 
Mineralocorticoids promote sodium and water retention, and potassium loss by kidney, but 
have no anti-inflammatory or anti-allergic effect. 
Cortisol, also known as hydrocortisone, is the major glucocorticoid in humans. It is 
synthesized by the cells of the zona fasciculata and zona reticularis of adrenal cortex; its 
secretion is regulated by the adrenocorticotropic hormone (ACTH) from anterior pituitary 
gland. Cortisol has a wide range of physiologic actions such as influencing carbohydrate, 
protein, and fat metabolism; regulation of blood pressure and cardiovascular function; and 
affecting immune system. 
Corticosteroid drugs are the synthetic analogs of cortisol hormone. They bind to specific 
intracellular receptors upon entering target tissues, and mimic the effects of the naturally 
occurring hormones; the main differences are the relative glucocorticoid versus 
mineralocorticoid potency and the long half-life that the synthetic analogs have. The 
relative potencies and duration of action of representative corticosteroids are presented in 
Table 1. 
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Compound 
Glucocorticoid 
potency 
Mineralocorticoid 
potency 
Duration of action 
Cortisol 1 1 short 
Cortisone 0.8 0.8 short 
Fludrocortisone 10 125 Intermediate 
Prednisone 4 0.8 Intermediate 
Prednisolone 4 0.8 Intermediate 
Methylprednisolone 5 0.5 Intermediate 
Triamcinolone 5 0 Intermediate 
Betamethasone 25 0 Long 
Dexamethasone 25 0 Long 
Short: 8-12 hours biologic half-life; Intermediate: 12-36 hours biologic half-life; Long: 36-72 hours biologic half-life. 
Adapted and modified from [1]  
Table 1. Relative potencies and equivalent doses of representative corticosteroids 
Glucocorticoids are used, either singly or in combination with other drugs, in the treatment 
of a wide variety of medical disorders. Some therapeutic indications for these drugs are as 
follows: 
 Musculoskeletal and connective tissue diseases (rheumatoid arthritis, polymyositis, 
systemic lupus erythematosus, and vasculitis) 
 Respiratory diseases (sarcoidosis and chronic bronchitis) 
 Gastrointestinal diseases (ulcerative colitis and crohn's disease) 
 Allergic disorders (asthma, hay fever, and allergic rhinitis) 
 Skin conditions (pemphigus, eczema, and dermatitis) 
 Eye diseases (conjunctivitis, uveitis, and optic neuritis) 
 Oral and maxillofacial diseases (lichen planus, keloid formation, and Bell's palsy) 
Although corticosteroids are widely used for treatment of diseases and conditions affecting 
oral and maxillofacial region, the scientific literature on this topic is limited and scattered 
throughout numerous journals and books. By gathering this scattered information, this 
chapter presents a concise review of various uses of corticosteroid drugs in the treatment of 
diseases affecting oral and maxillofacial region, and the role they have in reducing post-
operative morbidities such as pain, edema and trismus after various maxillofacial surgical 
procedures. The relation between maternal corticosteroid use and congenital maxillofacial 
deformities are explained. Also discussed is the perioperative management of patients 
receiving long-term therapeutic doses of corticosteroids. 
2. Uses of corticosteroids in the treatment of oral and maxillofacial 
diseases 
Corticosteroids are widely used in the treatment of diseases, disorders and conditions 
affecting the oral and maxillofacial area and the adjacent and associated structures. The 
diseases of the oral and maxillofacial region may be either local or the manifestation of a 
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systemic problem. Corticosteroids have their widest application in the management of acute 
and chronic conditions which have an allergic, immunologic, or inflammatory basis. 
Therefore, a group of corticosteroids which have predominantly a glucocorticoid activity 
and little or no mineralocorticoid action such as betamethasone, dexamethasone, 
triamcinolone, and prednisolone are used. 
The following are the main therapeutic indications for glucocorticoids in oral and 
maxillofacial diseases. 
2.1. Temporomandibular disorders (TMDs) 
TMDs are clinical problems involving the temporomandibular joints (TMJs), the masticatory 
muscles, or both. TMDs affect a significant number of individuals, and are the most common 
musculoskeletal disorders that cause orofacial pain. [2] Trauma to the joint structures, 
especially microtrauma, accounts for the majority of patients who develop TMJ problems. 
However, a small number of joint diseases are caused by nontraumatic etiologic factors 
including benign and malignant neoplasms (osteoma, chondroma, and synovial sarcoma), 
congenital or developmental anomalies (condylar agenesis and heperplasia), arthritides 
(rheumatoid arthritis), and systemic diseases. The most common signs and symptoms of 
TMDs are pain, altered mandibular movements, and the elicitation of joint noise.  
Treatment of TMDs varies according to their etiologic basis. Conservative managements 
(splint therapy, thermal application, pharmacotherapy, and physiotherapy), surgical 
treatments, or a combination of them may be required. A variety of medications have been 
used to relieve pain, inflammation, muscle spasm and other signs and symptoms associated 
with TMDs. They include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, 
analgesics, and muscle relaxants. 
Various glucocorticoids are used in the treatment of TMDs (Table 2). These drugs have 
dramatic effects on pain, hypomobility, and inflammation associated with acute TMJ 
problems. Oral corticosteroids are used mainly for treatment of acute TMJ discomforts or for 
diagnostic purposes. They should be used in a short term basis (tapering dose lasting 5 to 7 
days), and repeated as infrequently as possible. Long term use of corticosteroids for the 
treatment of TMDs is contraindicated; it can result in a cushing's- like disease process, acute 
adrenal crisis, hypertension, electrolyte abnormalities, diabetes, and formation of 
osteoporosis including the TMJ. [2] 
 
Drug Alternative name Usual dose
Hydrocortisone Hydrocortone 20-240 mg/day 
Prednisone Deltasone, Orasone 5-60 mg/day 
Prednisolone Delta-Cortef 5-60 mg/day 
Dexamethasone Decadron 0.75-9.0 mg/day 
Betamethasone Celestone 0.6-7.2 mg/day 
Adapted and modified from [2] 
Table 2. Oral corticosteroids used in TMDs 
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Intracapsular injection of glucocortcoids has been reported to decrease pain in patients with 
both pain and limited mouth opening secondary to inflammatory disorders of the joint, such 
as arthritis and capsulitis. [3-5] 
A number of mechanisms have been described for the anti-inflammatory actions of 
glucocorticoids. These drugs inhibit inflammatory mediator release from many cell types 
involved in inflammation such as macrophages, T-lymphocytes, mast cells, dendritic cells, 
and neutrophilic leukocytes. Glucocorticoids also reduce prostaglandin production by 
blocking the phospholipase A2 enzyme.  
The most striking effect of glucocorticoids is to inhibit the expression of multiple 
inflammatory genes encoding cytokines, chemokines, inflammatory enzymes, receptors and 
adhesion molecules. [6] Changes in gene transcription are regulated by proinflammatory 
transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1). These 
proinflammatory transcription factors switch on inflammatory genes via a process involving 
recruitment of transcriptional coactivator proteins and changes in chromatin modifications 
such as histone acetylation. Glucocorticoids exert their anti-inflammatory effect on 
responsive cells by binding and activating a cytoplasmic glucocorticoid receptor. The 
interaction between the activated glucocorticoid receptor and proinflammatory transcription 
factors may result in deacetylation of histones and repression of inflammatory genes. [7]  
In chronic inflammatory disorders of TMJ, macrophages, T-lymphocytes, and other cell 
types involved in inflammation release many cytokines and chemokines which will induce 
expression of adhesion molecules, release of variable enzymes from fibroblasts and 
osteoclasts and result in bone erosion. IL-8, which is a chemokine, is known to cause the 
infiltration of neutrophils into synovial fluid and promote joint inflammation. It was 
detected in 80% of the synovial tissue specimens taken from the TMJs with internal 
derangement. Similarly, IL-11 has been involved in the pathogenesis of osteoarthritis and 
rheumatoid arthritis. It has been found in synovial fluids of diseased temporomandibular 
joint and other joints. [8]  
Cytokines participate in various inflammatory processes and induce protease synthesis; 
their effects can be either synergic or inhibitory. In synovial joints, IL-1 α, IL-1 β and TNF-α 
induce synovitis and promote the production of proteinases resulting in degradation of 
cartilage, while IL-1ra works to block IL-1α and IL-1 β from binding to other cell receptors 
and has many beneficial effects on inflammatory diseases. [9] In a study by Nordahl et al. it 
was found that the local production of tumor necrosis factor-alpha (TNF-α) occured in the 
TMJ synovium of patients with chronic inflammatory connective tissue disease, and the 
severity of pain and tenderness of the TMJ was related to the level of TNF-α. [10] In a study 
by Frediksson et al., it was shown that the presence of TNF-α in the synovial fluid of TMJ 
predicted a positive treatment response to intra-articular glucocorticoid injection in patients 
with chronic TMJ inflammatory disorders. [11]  
Long-term complications associated with intra-articular glucocorticoid injection cannot be 
determined from the limited investigations done to date and thus remained unclear. 
Wenneberg et al. in a study evaluating the long-term prognosis of intra-articular 
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glucocorticoid injections for TMJ arthritis observed that this treatment modality was helpful, 
and there were no radiographically demonstrable side effects of the treatment. [12] In 
contrast, Haddad IK showed that intra-articular injections of corticosteroids (triamcinolone 
acetonide) cause damage to fibrous layer, cartilage, and bone of TMJ. [13] 
Juvenile idiopathic arthritis (JIA) is a chronic rheumatologic disease of children which may 
involve TMJ region, and cause significant craniofacial growth disturbances. The treatment of 
TMJ arthritis is controversial. It has been shown that glucocorticoid injection of the TMJ 
reduces pain and inflammation, and improves the function of TMJ in children with JIA. [14] 
Other studies also confirmed that corticosteroid injection of the TMJ can be safely performed 
in children with JIA, and is effective. [15-18] Few studies have evaluated TMJ corticosteroid 
injection in JIA. In these studies the volume of corticosteroid injected was chosen 
empirically. Treatment protocols such as injection of 1 cc (40 mg) of triamcinolone acetonide, 
1 cc (20 mg) of triamcinolone hexacetonidein, and 0.5 to 1 cc of the diluted (with 1% 
lidocaine HCL) triamcinolone hexacetonidein into each of the involved TMJs, all have been 
used in previous studies. [14-16] The peak effect occurs after approximately 6 weeks of 
treatment, and the expected duration is 6-17 months. The children may receive a second 
injection approximately 6 months after the first. [16] 
Side effects of intra-articular steroid injection in children include immediate reactions, such 
as pain and headache, or delayed side effects, such as joint infection and loss of 
subcutaneous fat. [16] Because the mandibular endochondral growth zone is located at the 
head of condyle (at the site of corticosteroid injection), the concern is whether intra-articular 
corticosteroid injection per se may cause growth retardation.  Stoustrup et al., in an animal 
study demonstrated that intra-articular glucocorticoid injection may result in even more 
pronounced mandibular growth reduction than that caused by the arthritis alone. [19] 
Schindler et al. reported a case of severe temporomandibular dysfunction and joint 
destruction after intra-articular injection of triamcinolone, and El-Hakim et al. showed TMJ 
resorption with active osteoclastic activity after intra-articular injection of a single dose of 
dexamethasone in rats. [20,21] 
intra-articular corticosteroid injection has been used to improve mouth opening in patients 
with anterior disk displacement without reduction (ADDWOR), i.e., closed lock. [22] 
2.2. Oral ulcerative and vesiculobullous lesions 
Corticosteroids are successfully used for the treatment of several ulcerative and 
vesiculobullous lesions involving the oral cavity and perioral areas including recurrent 
aphthous stomatitis (RAS), Behcet's syndrome, pemphigus vulgaris, bullous pemphigoid, 
mucous membrane pemphigoid, erythema multiforme and Stevens-Johnson syndrome 
(Tables 3-5). [23] 
Recurrent aphthous stomatitis: These superficial painful ulcers occur commonly in the oral 
cavity. Minor form of the disease has 1 to 5 ulcers at one episode. The ulcers which are 
under 1 cm in diameter persist 8 to 14 days, and heal spontaneously without sequelae. The 
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major aphthous ulcers are larger than 1 cm, and persist for weeks to months. Corticosteroids 
either alone or in combination with other drugs have been used for treatment of these 
lesions. [24-28] Topical steroids, such as triamcinolone acetonide and prednisolone (2 
times/day), are formulated as oral pastes. Therapeutic benefit can be derived from a 
mouthwash containing betamethasone. It should be noted that the long-term use of topical 
steroids may predispose patient to developing oral candidiasis. [28] 
Topical and injectable (intralesional) corticosteroids are useful for large and painful lesions. 
Systemic administration of corticosteroids is reserved for severe cases to prevent lesion 
formation or to reduce the number of lesions. Systemic corticosteroids should be prescribed 
in short courses, and only for severe outbreaks or cases that don't respond to topical or 
injectable corticosteroids. [23] 
Behcet's syndrome: The treatment of oral lesions of Behcet's syndrome is similar to the 
treatment of severe or major RAS. [23] 
Pemphigus vulgaris: Pemphigus vulgaris is a severe, potentially life-threatening 
vesiculobullous disease that may affect skin and mucous membranes. Oral cavity is 
involved in nearly 80% of patients. In the past, corticosteroid therapy was the treatment of 
choice but later, combination therapy involving the use of systemic corticosteroids with 
immunosuppressive agents was introduced, in an attempt to achieve disease control with 
lower doses of steroids. [29-31] 
The principal treatment of pemphigus vulgaris is systemic administration of corticosteroids 
at doses of 1 to 2 mg/kg/day. Maintenance of remission may be achieved with topical 
corticosteroids, allowing reduction of systemic drugs. Isolated lesions can be treated with 
injectable corticosteroids. [23] 
Bullous and mucous membrane pemphigoid: The choice of drugs used for the treatment of 
pemphigoid is based upon the sites of involvement, clinical severity, and disease 
progression. For more severe disease, or with rapid progression, systemic corticosteroids are 
the agents of choice for initial treatment, combined with steroid-sparing agents for long-
term maintenance. [32] Topical and injectable corticosteroids are useful for treatment of mild 
or localized oral lesions. [23] 
Erythema multiforme (EM) and Stevens-Johnson syndrome (SJS): It has been shown that 
corticosteroids have a favorable influence on the outcome of EM and SJS, if 
administered in high doses, over a short period of time, early in the course of the 
disease, and with proper tapering of medication. [33-37] However, the dosing and route 
of administration that provides the most benefit for EMM and SJS patients is in 
question. Treatment protocols such as early therapy with systemic prednisone (0.5 to 
1.0mg/kg/day) or pulse methylprednisolone (1mg/kg/day for 3 days), intravenous 
pulsed dose methylprednisolone (3 consecutive daily infusions of 20–30mg/kg to a 
maximum of 500mg given over 2 to 3 hours), and dexamethasone pulse therapy 
(1.5mg/kg IV over 30 to 60 minutes on 3 consecutive days), all have been shown to be 
effective. [33-35,37-39] 
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Drug Triamcinolone (10 mg/ml)          Dexamethasone (4 mg/ml) 
Indications Severe recurrent aphthous stomatitis,
 major aphthous stomatitis, erosive lichen planus 
Usual dosage Inject 0.1 cc/cm lesion
Contraindications 
Hypersensitivity to corticosteroids, systemic fungal infection, live 
vaccines, active tuberculosis
Common side effects Candidiasis, hyperglycemia
Unusual side effects 
Peptic ulceration with perforation, osteoporosis, impaired wound 
healing, mucosal atrophy
Adapted and modified from [23]. 
Table 3. Injectable (intralesional) corticosteroids used for treatment of oral lesions 
 
Drug Beclomethasone Betamethasone Clobetasol Halobetasol Fluocinonide 
Indications Severe recurrent aphthous stomatitis, 
Behcet's syndrome, pemphigus vulgaris, pemphigoid 
Administration Inhaler spray 
topically to 
mucosal lesions 
Topical intraoral 
cream or gel, 
soluble tablets as 
mouth wash
Topical 
intraoral 
cream or gel 
Topical 
intraoral 
cream or 
ointment
Topical 
intraoral cream 
Usual dosage 50-100 µg 
sprayed onto oral
lesion 
0.1% cream or 
0.05% gel 
applied thinly 
bid; 0.5 mg 2-4 
times daily as 
mouth wash
0.05% cream 
or gel applied 
thinly bid 
0.05% cream 
or ointment 
applied thinly 
bid 
0.05% cream 
applied thinly 
bid 
Contraindications Untreated infections
Common side effects Oral candidiasis
Unusual side effects Adrenal suppression if doses exceeded
Adapted and modified from [23]. 
Table 4. Topical corticosteroids used for treatment of oral lesions 
 
Drug Prednisone (tablets)
Indications Severe recurrent aphthous stomatitis, Behcet's syndrome, pemphigus 
vulgaris, pemphigoid, erythema multiforme
Usual dosage 1. 30-40 mg daily after breakfast for 4-5 days 
2. 1-2 mg/kg/day after breakfast until disease controlled  
3. 1-2 mg/kg/day, then maintenance of 2.5-15 mg daily  
4. 20-40 mg daily for 7-10 days at onset of lesions or until lesions resolve  
5. 60 mg daily for 2 days, 50 mg daily for 2 days, 40 mg daily for 2 days, 
30 mg daily for 2 days, 20 mg daily for 2 days, 10 mg daily for 2 days 
Contraindications Hypersensitivity to corticosteroids, systemic infection (unless specific 
antimicrobial therapy given), peptic disease (unless proton pump 
inhibitor given), live vaccines
Common side effects Dyspepsia, candidiasis, myopathy, osteoporosis, adrenal suppression,  
Cushing's syndrome, euphoria, depression
Unusual side effects Peptic ulceration with perforation, Cushingoid side effects increasingly 
likely with doses above 7.5 mg daily
Adapted and modified from [23]. 
Table 5. Systemic corticosteroids used for treatment of oral lesions 
 
Glucocorticoids – New Recognition of Our Familiar Friend 546 
2.3. Keloid and hypertrophic scars 
Keloid and hypertrophic scar (HS) represent pathologic overhealing conditions which are 
caused by excessive production of fibrous tissue following healing of skin injuries. Keloid 
produces significantly more collagen than HS. Their exact cause is unknown but 
inflammation, tension, and genetic background are mentioned as contributing factors. 
Keloid and HS have different clinical features. Keloids extend beyond the confines of the 
original wound, develop months after injury, and rarely regress. HS is a raised scar that 
remains confined to the area of the injury, usually form within weeks, and may regress 
without intervention. 
Various treatment modalities have been used for prevention and treatment of keloid and 
HSs such as pressure therapy, silicone gel sheeting, topical flavonoids, corticosteroid 
therapy, radiotherapy, and surgery. 
Topical and intralesional glucocorticoids are frequently used to treat existing keloid and HS 
or, prophylactically, to prevent their formation or recurrence after surgical removal. Topical 
administration of steroids doesn't appear to be as efficacious as intralesional injection of the 
drug. Intralesional steroid injection, either on its own or in combination with other 
treatment modalities is the most common treatment used for keloid and HSs. 
Glucocorticoids have a multiplicity of effects on scars including suppressive effects on the 
inflammatory process in the wound, diminishing collagen and glycosaminoglycan 
synthesis, inhibition of fibroblast growth, and enhancing collagen and fibroblast 
degeneration. [40,41] Triamcinolone acetonide is the most commonly used steroid for the 
treatment of HS and keloid. It is used in a concentration of 10-20 mg/ml, though it can be 
given at a dose of 40 mg/ml for a tough bulky lesion; the concentration depends upon the 
size and site of the lesion and age of the individual. [42] Side effects of steroid injection 
include hypopigmentation, dermal atrophy, telangiectasia, and cushingoid effects from 
systemic absorption. [41] Cushing's syndrome secondary to injection of triamcinolone 
acetonide for the treatment of keloids have been reported by several investigators. [43,44]  
2.4. Central giant cell granuloma 
Central giant cell granuloma of the jaws is a benign tumor which occurs most often in 
children and young adults. This tumor is made up of loose fibrous connective tissue stroma 
with many interspersed proliferating fibroblasts, aggregations of multinucleated giant cells, 
and foci of hemorrhage. 
Various surgical and nonsurgical treatments have been advocated for this lesion. One of the 
nonsurgical treatments proposed is intralesional corticosteroid injections. Intralesional 
injection of triamcinolone acetonide has been shown to induce partial and in some cases 
complete resolution of central giant cell granuloma. However, there is no reasonably strong 
consensus in the literature regarding optimal dosage and duration of treatment that 
provides the most benefit. The mechanism of action of corticosteroids in the treatment of 
central giant cell granuloma is unknown. A rationale for its use has been the histologic 
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resemblance of central giant cell granuloma to sarcoid. Because corticosteroids have been 
effective in the treatment of sarcoid, it was thought that they may have a similar therapeutic 
effect on central giant cell granuloma. In addition, corticosteroids may act by suppressing 
any angiogenic component of the lesion. [45] 
2.5. Bell's palsy  
Bell's palsy is an idiopathic inflammation of the facial nerve (the seventh of twelve paired 
cranial nerves) which occurs almost always on one side only. It is characterized by facial 
muscle weakness, hyperacusis, decreased tearing, and loss of taste on the anterior two thirds 
of the tongue. Because Bell's palsy results from inflammation and edema of the facial nerve, 
corticosteroids constitute the standard medicine in the treatment of this condition. [46-48] 
For adults, prednisolone at doses of 1 mg/kg/day for 7 to 10 days, taken in divided doses in 
the morning and evening, is suggested.  
2.6. Management of post-operative morbidities associated with maxillofacial 
surgeries 
Facial pain, edema, ecchymosis and limitation of mouth opening are the expected sequelae 
of oral and maxillofacial surgeries. These post-operative complications affect the ability of 
patient to interrelate and to return to the daily life and activities, and deteriorate the quality 
of life of patient. [49,50] 
Many modalities are used to abate sequelae in the oral and maxillofacial surgery including 
use of ice pack, pressure dressing, surgical drain, and drugs.  
Corticosteroids are commonly used to control post-operative morbidities and to provide 
comfort for patients. However, there are no definite protocols relative to molecules, doses, 
schedules, and routes of administration. [51] The most commonly administered types of 
corticosteroids are betamethasone, dexamethasone, and methylprednisolone, administered 
intravenously, orally or by injection into the masseter muscle. The morbidity-management 
protocol also varies depending upon the type of surgery being performed. 
To decrease post-rhinoplasty edema, the administration of corticosteroids has been 
advocated for many years. In a study by Gurlek et al., it was shown that high dose 
methylprednisolone was effective in preventing and reducing both the periorbital 
ecchymosis and edema in open rhinoplasty. [52] In the same line, Kargi et al., and Kara and 
Gokalan showed that the perioperative use of corticosteroids reduced edema and 
ecchymosis associated with rhinoplasty surgery. [53,54] In contrast, Hoffmann et al. did not 
observe any increase either in the edema or the ecchymosis after rhinoplasty surgery. [55]  
Regarding orthognathic surgery, several investigations demonstrated that perioperative 
corticosteroid administration significantly reduced post-operative inflammation and edema. 
[56-59] In contrast, Munro et al. did not observe any significant decrease in postoperative 
edema even with the highest doses and the longest durations of corticosteroid treatment. (56) 
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The effects of corticosteroids on post-operative edema after oral surgery have been widely 
investigated in the literature. Many prior studies demonstrated a significant decrease in 
post-operative edema after administration of corticosteroids. [60-63] In a study by Zandi, it 
was shown that steroids not only reduced the facial swelling, but also the severity of pain 
after surgery. [60] Similarly, several studies reported that corticosteroids significantly 
decreased post-operative edema and pain, indicating a strong correlation between edema 
and pain decreases. [62-64] 
Even though the effects of corticosteroids on post-operative morbidities after various oral 
and maxillofacial surgeries have been widely investigated in the literature, methodological 
differences, variation in agents, doses, and routes of administration of the drugs have 
compromised the scientific conclusions. 
2.7. Other uses of corticosteroids in oral and maxillofacial surgery 
In addition to the aforementioned indications, corticosteroids are successfully used in the 
management of acute trigeminal nerve injuries, traumatic facial nerve paralysis, chronic 
facial pain, and allergic diseases involving maxillofacial area. 
3. Corticosteroids contraindications  
In prescribing corticosteroids, physicians must be aware that some patients are poor 
candidates for systemic, locally injected, or topical corticosteroid therapy.      
Systemic corticosteroids must be used with the greatest of caution in patients with 
uncontrolled hypertension, diabetes, active peptic ulcer, heart diseases, infections, 
psychiatric disorders, osteoporosis, cataract, glaucoma, tuberculosis, mycobacterial diseases, 
herpes simplex infection, pregnancy, varicella zoster infection, immune deficiency, 
underactive thyroid, and mental disorders. 
Injectable corticosteroid use is contraindicated in patients with hypersensitivity to 
corticosteroids, infections, and active tuberculosis.  
Use of topical corticosteroids is absolutely contraindicated in the treatment of primary 
bacterial infections such as impetigo, furuncles, carbuncles, erysipelas, cellulitis, 
lymphangitis, and erythrasma. Topical corticosteroids are also contraindicated in patients 
with a history of hypersensitivity to any of the components of the preparation. Currently, 
little is known about the safety of topical corticosteroids in pregnancy. Although it has been 
reported that there is an association between very potent topical corticosteroids and 
congenital abnormalities including low birth weight and orofacial clefts, use of these drugs 
in pregnancy is not recommended unless the potential benefit justifies the potential risks to 
fetus. [65] 
Ophthalmic use of topical corticosteroids is contraindicated in most viral, bacterial, and 
fungal diseases of ocular structures. 
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4. Corticosteroids side effects 
Although corticosteroids have great potential in the treatment of various diseases and 
conditions affecting oral and maxillofacial region, they also carry the risk of many side 
effects. Therefore, benefits from corticosteroids should always be weighed against their 
potential risks. Side effects of corticosteroids vary depending on the type and dose of the 
medication, rout of administration, and length of treatment. Significant adverse effects are 
most likely to occur in patients using oral corticosteroids for a long period of time. These 
may include weight gain, impaired growth, adrenal insufficiency, electrolyte abnormalities, 
increased susceptibility to infection, myopathy, osteoporosis, osteonecrosis, cataract, 
glaucoma, psychological problems, fractures, hypertension, insomnia, moon face, diabetes, 
and peptic ulcer. [1,66]  
Topical glucocorticoids may cause adverse effects such as skin atrophy, 
hypopigmentation, subcutaneous fat wasting, telangectasia, contact dermatitis, oral 
thrush, and cushingoid effects from systemic absorption. [28,41] Application of topical 
corticosteroids on eyelids has been reported to cause glaucoma. Adrenal suppression, 
growth retardation in children, and cushing's syndrome are rare adverse effects of long 
term topical corticosteroid use.  
Intralesional glucocorticoids may cause sterile abscess, skin atrophy, hypopigmentation, 
panniculitis, and skin necrosis. 
Although the frequency of side effects of inhaled corticosteroids is lower than systemic 
corticosteroids, high doses of inhaled corticosteroids have the potential to produce various 
local and systemic side effects. Systemic side effects associated with inhaled corticosteroids  
include osteoporosis, retarded growth in children, cataracts, glaucoma, and skin thinning. 
Inhaled corticosteroids may cause local side effects including oropharyngeal candidiasis, 
dysphonia, reflex cough, bronchospasm, and pharyngitis. [67] 
5. Perioperative management of patients with adrenal insufficiency 
Insufficient adrenocortical function is a rare disorder resulting from endogenous deficiency 
(primary) or from the administration of exogenous corticosteroids (secondary). Adrenal 
suppression should be suspected in those patients receiving the equivalent of 20 mg of 
prednisone daily for one week or the equivalent of 7.5 mg of prednisone daily for one 
month within the past year. [2] In adrenal suppression the body is not able to appropriately 
manage the challenge of stresses such as medical illness, surgery, and trauma. This may 
precipitate an adrenal crisis, signaled by the onset of fever, restlessness, flank and 
abdominal pain, vomiting, lethargy, hypotension, or coma.  
Any patient suspected of having adrenal insufficiency should be evaluated with an ACTH 
(cortrosyn) stimulation test or be given supplemental corticosteroids empirically 
perioperatively. Cortrosyn stimulation test measures how well the adrenal glands respond 
to a synthetic ACTH administered to the patient. 
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The currently recommended corticosteroid coverage for various surgical procedures is 
based on the magnitude of stress and the known glucocorticoid production rate associated 
with it, and includes the following: [2,68] 
 Minor surgical stress such as tooth extraction, biopsy, periodontal surgery, genioplasty, 
etc: 25 mg of hydrocortisone equivalent, the day of surgery 
 Moderate surgical stress such as panfacial fractures, two jaw surgery, etc: 50-75 mg of 
hydrocortisone equivalent for 1 to 2 days. 
 Major surgical stress such as extensive head and neck resection and reconstruction, etc: 
100-150 mg of hydrocortisone equivalent for 2 to 3 days. 
In the case of postoperative complications such as fever and pain, it is recommended that 
the corticosteroid administration be continued consistent with the post-operative stress 
response. [68] 
6. Maternal corticosteroid use and the risk of orofacial clefts in infants  
Orofacial clefts are the most common congenital deformity affecting maxillofacial area. The 
etiology of facial clefting is complex and has been extensively investigated. There are both 
major and minor genetic influences involved, with variable interactions from environmental 
factors. [69] Several environmental factors such as maternal drug intake, trauma, smoking, 
and exposure to x-rays during the pregnancy period have been suggested to increase the 
chance of cleft development in infants. [70]  
Pregnant women often use topical, inhaled, or systemic corticosteroid drugs for a variety of 
inflammatory and allergic conditions. Several investigations have reported that the use of 
corticosteroids during early pregnancy is associated with a 3- to 6-fold increased risk of 
orofacial clefts. [71-75] Although systemic corticosteroids are associated with a higher risk of 
orofacial clefts than topical corticosteroids, the latter is not without risk. It has been shown 
that application of hydrocortisone cream on eczematous skin is associated with significant 
increase in the level of plasma cortisol. [76] In a study by Edwards et al., a significant 
association between topical corticosteroids and orofacial cleft was observed. [77] 
Epidemiologic data have shown that low-to-moderate doses of inhaled corticosteroids taken 
during the first trimester of pregnancy are safe but raise concerns about high doses. [78]  
The mechanism of cleft palate production by corticosteroids is uncertain; it is a complicated 
interference in a complex developmental program involving many genetic and biochemical 
processes. Glucocorticoids may cause cleft palate deformity by delaying palatal shelf elevation. 
[79] Corticosteroids can reduce the collagen content of connective tissue by inhibiting collagen 
synthesis, which could disrupt cell-cell interaction and tissue-tissue interactions. [71] 
7. Conclusion 
Glucocorticoids are used, either singly or in combination with other drugs, for the treatment 
of various diseases affecting oral and maxillofacial area. They are also frequently used to 
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minimize expected post-operative morbidities such as pain and edema after oral and 
maxillofacial surgeries. Because of anti-inflammatory and anti-allergic actions of 
glucocorticoids, they have their widest application in the management of acute and chronic 
conditions which have allergic, immunologic, or inflammatory basis. However, 
corticosteroids carry the risk of potential side effects which are sometimes severe and life 
threatening. Therefore, benefits from corticosteroids should always be weighed against their 
potential risks in each patient. 
Prescribing the minimal dose and the least potent type of corticosteroids necessary to 
produce a given therapeutic effect, simultaneous use of non-steroidal agents to reduce the 
dose of corticosteroids, and prescribing corticosteroids for a short period of time or 
sporadically are some strategies to minimize corticosteroids adverse effects.  
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